Clinical Trial Update: Erlotinib and Sirolimus for the Treatment of Metastatic Renal Cell Carcinoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of erlotinib and sirolimus for metastatic renal cell carcinoma has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Sirolimus (Sirolimus)

Snippet

Sponsor: University of Colorado, Denver | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED | Results posted: 2014-02-17